|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our study highlighted CAF-promoted DNM3OS as an attractive target to reverse tumor radioresistance in ESCC.
|
30463848 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In our immunohistochemical investigation of ESCC tissues, we observed that the intensity of expression of two CAF markers-alpha smooth muscle actin (αSMA) and fibroblast activation protein (FAP)-in the tumor stroma was significantly correlated with the depth of tumor invasion, lymph node metastasis, advanced pathological stage, and poor prognosis.
|
30683902 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Conclusion:</b> These new NBs, which combines the advantages of targeted theranostic agent and CEUI, is expected to be a potential approach for tumor therapy based on CAF targeting.
|
31749406 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CHAF1A promotes tumor growth while its impact on chemotherapy outcome remains unknown.
|
31377317 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Efforts to develop new treatments targeting the tumour mesenchyme are hampered by a poor understanding of the mechanisms underlying the development of CAF.
|
29506142 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
αAMR and AM22-52 therapies significantly suppressed the growth of CAFs/MCF-7 tumors.
|
28178651 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we examined 41 cases of neuroblastoma using immunohistochemistry for the tumour-associated macrophage (TAM) markers CD68, CD163, and CD204, and a cancer-associated fibroblast (CAF) marker, alpha smooth muscle actin (αSMA).
|
27425378 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Similar analyses performed on ten additional TCGA cancer datasets revealed that other tumor types shared CAF markers with OSCC, including PDGFRβ, which was found to significantly correlate with the reference collagen expression in ten of the 11 cancer types tested.
|
27128408 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The five-year survival rate of patients with CHAF1A-positive tumors was remarkably lower than that of patients with CHAF1A-negative tumors.
|
24845563 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, two molecules (ASPN and STC1) marked overlapping and distinct subregions of stroma associated with tumour epithelia and may represent new CAF markers.
|
21804603 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tissue microarray-based evaluation of Chromatin Assembly Factor-1 (CAF-1)/p60 as tumour prognostic marker.
|
23109837 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The hazard ratio in the CAF-rich type of tumor microenvironment was 4.85 (95% CI 1.41-16.6, versus the CAF-poor) when adjusted by proportional hazards modeling for the center where the patient was managed, gender, tumor stage, presence of neck metastasis and age at diagnosis.
|
21112238 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim was to investigate CAF-1 as a proliferation marker in a wide variety of solid tumours, and to assess its potential value in predicting clinical outcome.
|
21083601 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Because topoisomerase IIalpha (Topo-IIalpha) is a target for doxorubicin and is coamplified in 20% to 50% of HER2-amplified tumors, we postulated that Topo-IIalpha copy number might account for the benefit from CAF dose escalation in HER2-positive tumors.
|
19470942 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, high p150 expression was more frequently seen in tumors at early invasive stages (p < 0.005), in tumors without metastases (both local and distant, p < 0.005) and in early TNM stages (p < 0.005) in general.
|
15382063 |
2004 |